Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424217 | 0.90 | S1PR1 (0.51) | S1PR1S1PR3S1PR5S1PR4CYP2C9 | |
| SCHEMBL946557 | 0.88 | S1PR1 (0.48) | S1PR1S1PR3S1PR5S1PR4CYP2C9 | |
| SCHEMBL3426610 | 0.87 | S1PR1 (0.44) | S1PR1S1PR3S1PR5S1PR4CYP2C9 | |
| SCHEMBL3426893 | 0.86 | S1PR1 (0.42) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL3428589 | 0.84 | S1PR1 (0.50) | S1PR1S1PR3S1PR5S1PR4CYP2C9 | |
| SCHEMBL948510 | 0.83 | S1PR1 (0.49) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3431435 | 0.83 | S1PR1 (0.48) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3428620 | 0.83 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL946682 | 0.82 | S1PR1 (0.44) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3428648 | 0.82 | S1PR1 (0.41) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | claimed |
| WO-2011005290-A1 | DISUBSTITUTED OXADIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2252615-A1 | DIHYDRO- 1H- PYRROLO [1,2-A]INDOL-1-YL CARBOXYLIC DERIVATIVES WHICH ACT AS S1P1 AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009094157-A1 | DIHYDRO- 1H- PYRROLO [1,2-A] INDOL-1-YL CARBOXYLIC DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.